|Bid||0.9300 x 0|
|Ask||0.9400 x 0|
|Day's Range||0.9300 - 0.9800|
|52 Week Range||0.6500 - 2.6000|
|Beta (5Y Monthly)||0.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 21, 2023 - Mar 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
Cardiol Therapeutics CEO David Elsley shared news the company has hit a major milestone in that the first patient has been enrolled in a Phase II open-label pilot study of CardiolRx in patients wit...
The Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study Oakville, Ontario--(Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced today that the first patient has been enrolled in the Company-sponsored Phase II open-label pilot
Announces the initiation of a Phase II open-label pilot study (NCT05494788), to investigate the tolerance, ...